Immune Deregulation in Sepsis and Septic Shock: Reversing Immune Paralysis by Targeting PD-1/PD-L1 Pathway
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Sepsis remains a major problem for human health worldwide, thereby manifesting high rates of morbidity and mortality. Sepsis, once understood as a monophasic sustained hyperinflammation, is currently recognized as a dysregulated host response to infection, with both hyperinflammation and immunoparalysis occurring simultaneously from the earliest stages of sepsis, involving multiple organ dysfunctions. Despite the recent progress in the understanding of the pathophysiology underlying sepsis, no specific treatment to restore immune dysregulation in sepsis has been validated in clinical trials. In recent years, treatment for immune checkpoints such as the programmed cell death protein 1/programmed death ligand (PD-1/PD-L) pathway in tumor-infiltrating T-lymphocytes has been successful in the field of cancer immune therapy. As immune-paralysis in sepsis involves exhausted T-lymphocytes, future clinical applications of checkpoint inhibitors for sepsis are expected. In addition, the functions of PD-1/PD-L on innate lymphoid cells and the role of exosomal forms of PD-L1 warrant further research. Looking back on the history of repeatedly failed clinical trials of immune modulatory therapies for sepsis, sepsis must be recognized as a difficult disease entity for performing clinical trials. A major obstacle that could prevent effective clinical trials of drug candidates is the disease complexity and heterogeneities; clinically diagnosed sepsis could contain multiple sepsis subgroups that suffer different levels of hyper-inflammation and immune-suppression in distinct organs. Thus, the selection of appropriate more homogenous sepsis subgroup is the key for testing the clinical efficacy of experimental therapies targeting specific pathways in either hyperinflammation and/or immunoparalysis. An emerging technology such as artificial intelligence (AI) may help to identify an immune paralysis subgroup who would best be treated by PD-1/PD-L1 pathway inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
The epidemiology of sepsis in the United States from 1979 through 2000
Martin, G. S., Mannino, D. M., Eaton, S., & Moss, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022139 · Cited by 5,841 · cited 1×
“Sepsis is one of the leading causes of death in intensive care units (1, 2).”
BackgroundMolecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652 · cited 1×
“Specifically, they first lose IL-2 production and their high proliferative capacity, followed by a decrease in the production of IFNg, TNF, and chemokines (69).”
BackgroundNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“For example, Nivolumab, a human monoclonal antibody to PD-1, is used for the treatment of advanced melanoma (98).”
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Type I interferons in infectious disease
McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780 · cited 1×
“IFNs are a group of signaling proteins that have diverse effects on the innate immune system (20).”
BackgroundBig Data and Machine Learning in Health Care
Beam, A. L., & Kohane, I. S. (2018) · JAMA · doi:10.1001/jama.2017.18391 · Cited by 2,506
Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia
Tracey, K. J., Fong, Y., Hesse, D. G., Manogue, K. R., Lee, A. T., Kuo, G. C., Lowry, S. F., & Cerami, A. (1987) · Nature · doi:10.1038/330662a0 · Cited by 2,448 · cited 1×
“Preclinical studies using animal model experiments have shown favorable results: a protective effect against sepsis (34, 35).”
ResultThrombosis as an intravascular effector of innate immunity
Engelmann, B., & Massberg, S. (2013) · Nature Reviews Immunology · doi:10.1038/nri3345 · Cited by 1,989
The immunopathology of sepsis and potential therapeutic targets
van der Poll, T., van de Veerdonk, F. L., Scicluna, B. P., & Netea, M. G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.36 · Cited by 1,957 · cited 2×
“receptors (RLRs) and C-type lectin receptors (CLRs) (8, 16).”
BackgroundDetection of circulating tumor necrosis factor after endotoxin administration
Michie, H. R., Manogue, K. R., Spriggs, D. R., Revhaug, A., O'Dwyer, S., Dinarello, C. A., Cerami, A., Wolff, S. M., & Wilmore, D. W. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806093182301 · Cited by 1,677 · cited 1×
“Among inflammatory proteins, TNF-a is a pro-inflammatory cytokine that has been shown to increase in the blood after endotoxin administration (31).”
BackgroundDerivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
Seymour, C. W., Kennedy, J. N., Wang, S., Chang, C.-C. H., Elliott, C. F., Xu, Z., Berry, S., Clermont, G., Cooper, G., Gomez, H., et al. (2019) · JAMA · doi:10.1001/jama.2019.5791 · Cited by 1,567
The surviving sepsis campaign bundle: 2018 update
Levy, M. M., Evans, L. E., & Rhodes, A. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5085-0 · Cited by 1,445
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
Poggio, M., Hu, T., Pai, C.-C., Chu, B., Belair, C. D., Chang, A., Montabana, E., Lang, U. E., Fu, Q., Fong, L., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.016 · Cited by 1,376
Komorowski, M., Celi, L. A., Badawi, O., Gordon, A. C., & Faisal, A. A. (2018) · Nature Medicine · doi:10.1038/s41591-018-0213-5 · Cited by 1,290
Monocyte deactivation in septic patients: Restoration by IFN-γ treatment
Döcke, W.-D., Randow, F., Syrbe, U., Krausch, D., Asadullah, K., Reinke, P., Volk, H.-D., & Kox, W. (1997) · Nature Medicine · doi:10.1038/nm0697-678 · Cited by 1,190 · cited 1×
“IFNg has been shown to improve phagocytic capacity and HLA-DR expression on monocytes in human sepsis and related to earlier recovery from sepsis (88).”
BackgroundA clinically applicable approach to continuous prediction of future acute kidney injury
Tomašev, N., Glorot, X., Rae, J. W., Zielinski, M., Askham, H., Saraiva, A., Mottram, A., Meyer, C., Ravuri, S., Protsyuk, I., et al. (2019) · Nature · doi:10.1038/s41586-019-1390-1 · Cited by 1,086
Adjunctive glucocorticoid therapy in patients with septic shock.
Venkatesh, B., Finfer, S., Cohen, J., Rajbhandari, D., Arabi, Y., Bellomo, R., Billot, L., Correa, M., Glass, P., Harward, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705835 · Cited by 1,037 · cited 1×
“The APROCCHS (Activated Protein C and Corticosteroid for Human Septic Shock) trail, which compared activated protein C, low does corticosteroid, their combination, and placebo, demonstrated that sepsis patients treated with corticosteroid showed a significantly improved 90-day mortality rate (29), while the ADRENAL (A…”
BackgroundCorticosteroid insufficiency in acutely ill patients
Cooper, M. S., & Stewart, P. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020529 · Cited by 1,033 · cited 1×
“Relative adrenal insufficiency, also known as critical illnessrelated corticosteroid insufficiency, occurs in critically ill patients (26).”
BackgroundIncreased mortality associated with growth hormone treatment in critically ill adults
Takala, J., Ruokonen, E., Webster, N. R., Nielsen, M. S., Zandstra, D. F., Vundelinckx, G., & Hinds, C. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909093411102 · Cited by 1,023 · cited 1×
“Moreover, growth hormone treatment was associated with prolonged mechanical ventilation, ICU stays and in-hospital admission days (86).”
BackgroundHydrocortisone plus fludrocortisone for adults with septic shock.
Annane, D., Renault, A., Brun-Buisson, C., Megarbane, B., Quenot, J.-P., Siami, S., Cariou, A., Forceville, X., Schwebel, C., Martin, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705716 · Cited by 939 · cited 1×
“The APROCCHS (Activated Protein C and Corticosteroid for Human Septic Shock) trail, which compared activated protein C, low does corticosteroid, their combination, and placebo, demonstrated that sepsis patients treated with corticosteroid showed a significantly improved 90-day mortality rate (29), while the ADRENAL (A…”
BackgroundGentile, L. F., Cuenca, A. G., Efron, P. A., Ang, D., Bihorac, A., McKinley, B. A., Moldawer, L. L., & Moore, F. A. (2012) · Journal of Trauma and Acute Care Surgery · doi:10.1097/ta.0b013e318256e000 · Cited by 801 · cited 3×
“Persistent Inflammation, Immunosuppression, and Catabolism Syndrome (PICS) is an intriguing concept from the integrated point of view, which contends that SIRS and its counterpart CARS do not exist independently; rather, both are occurring simultaneously.”
BackgroundInfluentialThe Surviving Sepsis Campaign Bundle: 2018 Update
Levy, M. M., Evans, L. E., & Rhodes, A. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000003119 · Cited by 679
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592 · cited 1×
“Therapeutic efficacy of Ipilimumab has been reported to correlate with the ability of receptors binding to Ipilimumab, indicating the importance of interaction between ligand and receptor of immune check point pathway (82).”
BackgroundCD4 + T-cell subsets in inflammatory diseases: beyond the T h 1/T h 2 paradigm
Hirahara, K., & Nakayama, T. (2016) · International Immunology · doi:10.1093/intimm/dxw006 · Cited by 417 · cited 1×
“The Th1/Th2 paradigm cannot completely explain the role of current known helper T cells (68).”
BackgroundVenet, F., Pachot, A., Debard, A.-L., Bohe, J., Bienvenu, J., Lepape, A., Powell, W. S., & Monneret, G. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.9.6540 · Cited by 158
Cited by
Multi-Omics Endotypes in ICU Sepsis-Induced Immunosuppression
Garduno, A., Cusack, R., Leone, M., Einav, S., & Martin-Loeches, I. (2023) · Microorganisms · doi:10.3390/microorganisms11051119 · Cited by 39
“Other novel therapies that have shown some promising potential benefits are immunoglobulins, non-neutralizing ADM-binding Ab adrecizumab [101,102] has also been shown to inhibit the production of pro-inflammatory cytokines, monoclonal antibodies targeting checkpoint molecules, such as programmed-death 1 protein (PD-1)…”
Background
Metadata
- Authors
- Nakamori, Y., Park, E. J., & Shimaoka, M.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2021-02-17
- Volume
- 11
- Pages
- 624279-624279
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3129461204
- Cited by
- 163
- References
- 27
- FWCI
- 15.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.